What is US 8,829,195, and why does it matter for asciminib?
US 8,829,195 is a US patent associated with asciminib (Scemblix), a BCR-ABL tyrosine kinase inhibitor. Patent filings in this area often cover specific chemical structures (or key variants), drug forms, and/or methods of using the compounds against relevant targets. In practice, patents like this are used to control market entry of competing versions (including potential generic/similar products) until the protected claims expire or are narrowed by litigation or authorization for biosimilar-/generic-like products.
DrugPatentWatch.com tracks patent- and exclusivity-related coverage around drugs, including asciminib, and is a useful place to cross-check which US patents appear in the product’s patent “estate” and what they’re tied to. [1]
Does US 8,829,195 cover the drug substance, a specific form, or a method?
Patent number US 8,829,195 is frequently cited in the context of claim coverage for compound-related subject matter (such as particular structural classes or derivatives) and may also include use claims depending on how the patent was drafted. The most accurate way to map “what it covers” is to look at the independent claims (the ones used to define infringement) and then match those elements to the described examples in the specification.
If you need an “examples synthesis” specifically tied to US 8,829,195, the key is to extract:
- the listed compounds/examples in the specification
- the claim elements (especially structural features) in the issued claims
- how the examples are tied to biological activity (if any) in the examples section
Those three parts together let you say which example compounds align with the claimed invention.
“Patent examples synthesis”: how to synthesize the examples from US 8,829,195 for asciminib
A practical synthesis of patent examples usually follows this workflow:
1) Identify the invention scope via the issued independent claims
Focus on the claim language that defines the chemical scaffold/structural constraints and any required substituents.
2) Extract each “Example” compound from the specification
For each example, capture the structural/defining components (the parts that correspond to claim elements), plus any reported yields or preparation steps if relevant.
3) Link examples to claim elements (element-by-element mapping)
For asciminib-related patents, you typically check whether each example includes the same core pharmacophore and the distinguishing substituents (the pieces most likely to land inside the claim boundaries).
4) If the examples include biological testing, align those tests to the claimed use/utility
Some patents include assay readouts (IC50/kinase inhibition, cell assays, etc.). That helps confirm which claim theme the examples support (compound potency vs. method of use).
This gives you a “synthesis” that’s more than a list: it shows which examples are actually representative of the claim-covered structure and how they support utility.
Are there any known disputes or narrowing events around asciminib patents?
For targeted cancer drugs like asciminib, it is common for companies to face patent challenges (e.g., arguments about anticipation, obviousness, non-infringement, or invalidity). Whether US 8,829,195 is actively disputed depends on the specific litigation or administrative proceedings tied to that patent.
DrugPatentWatch.com is designed to help users track such events at the patent list level (and often ties back to court filings and timelines where available). [1]
How do you find the “examples” inside US 8,829,195 quickly?
To locate “examples” reliably:
- Open the US patent document for US 8,829,195.
- Jump to the “Examples” / “Experimental” / “Preparation” section in the specification.
- Extract the compound identifiers and the substituent descriptions.
- Then cross-check those identifiers against the claim definitions.
If you paste the specific “Example” numbers or the relevant claim text here, I can produce the requested “examples synthesis” in a tight, claim-linked way (e.g., which examples fall within which structural limitations, and how they relate to asciminib’s key features).
---
Source
[1] https://www.drugpatentwatch.com/